WOL treatment downregulated the colonic expression of Il6, leading to a decrease in cytokines delivered to the liver, thereby resulting in the upregulation of Scd1 and preventing the onset of an early event prior to IBD clinical symptoms. This evidence concerns the gene IL6 and inflammatory bowel disease.